Genetically engineered mouse models (GEMMs) of cancer have been instrumental in studying cancer initiation, progression and evolution. There is great interest now in the mouse as a preclinical tool to identify new therapies and predict current regimes. However there are many differences between mouse and man; for example, drug metabolism and the immune system. This session will address current GEMM models to investigate drug treatments and the state of art work undergoing to humanise mouse models.